Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update
27 Julho 2023 - 6:00PM
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical
company focused on the development and commercialization of novel
products for serious rare and ultrarare genetic diseases, today
announced that it will host a conference call at 5:00 p.m. ET on
Thursday, August 3, 2023, to discuss its financial results and
corporate update for the quarter ending June 30, 2023.
The live and replayed webcast of the call will be available
through the company’s website at
https://ir.ultragenyx.com/events-presentations. To participate in
the live call, please register by clicking on the following link
(registration link) and you will be provided with dial-in details.
The replay of the call will be available for one year.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing
novel therapies to patients for the treatment of serious rare and
ultrarare genetic diseases. The company has built a diverse
portfolio of approved medicines and treatment candidates aimed at
addressing diseases with high unmet medical need and clear biology,
for which there are typically no approved therapies treating the
underlying disease.
The company is led by a management team experienced in the
development and commercialization of rare disease therapeutics.
Ultragenyx’s strategy is predicated upon time- and cost-efficient
drug development, with the goal of delivering safe and effective
therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's
website at: www.ultragenyx.com.
ContactsUltragenyx Pharmaceutical,
Inc.InvestorsJoshua Higa415-475-6370IR@ultragenyx.com
MediaJeff Blake415-612-7784media@ultragenyx.com
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Ultragenyx Pharmaceutical (NASDAQ:RARE)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024